165 related articles for article (PubMed ID: 22537109)
21. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.
Okimoto RA; Lin L; Olivas V; Chan E; Markegard E; Rymar A; Neel D; Chen X; Hemmati G; Bollag G; Bivona TG
Proc Natl Acad Sci U S A; 2016 Nov; 113(47):13456-13461. PubMed ID: 27834212
[TBL] [Abstract][Full Text] [Related]
22. Identification and synthesis of N-(thiophen-2-yl) benzamide derivatives as BRAF(V600E) inhibitors.
Xie Y; Chen X; Qin J; Kong X; Ye F; Jiang Y; Liu H; Jiang H; Marmorstein R; Luo C
Bioorg Med Chem Lett; 2013 Apr; 23(8):2306-12. PubMed ID: 23489628
[TBL] [Abstract][Full Text] [Related]
23. Identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea hydrochloride (CEP-32496), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF) V600E.
Rowbottom MW; Faraoni R; Chao Q; Campbell BT; Lai AG; Setti E; Ezawa M; Sprankle KG; Abraham S; Tran L; Struss B; Gibney M; Armstrong RC; Gunawardane RN; Nepomuceno RR; Valenta I; Hua H; Gardner MF; Cramer MD; Gitnick D; Insko DE; Apuy JL; Jones-Bolin S; Ghose AK; Herbertz T; Ator MA; Dorsey BD; Ruggeri B; Williams M; Bhagwat S; James J; Holladay MW
J Med Chem; 2012 Feb; 55(3):1082-105. PubMed ID: 22168626
[TBL] [Abstract][Full Text] [Related]
24. Discovery of a novel pan-RAF inhibitor with potent anti-tumor activity in preclinical models of BRAF
Hong SP; Ahn SK
Life Sci; 2017 Aug; 183():37-44. PubMed ID: 28645859
[TBL] [Abstract][Full Text] [Related]
25. Synthesis, biological evaluation and molecular docking of novel 5-phenyl-1H-pyrazol derivatives as potential BRAF(V600E) inhibitors.
Dong JJ; Li QS; Wang SF; Li CY; Zhao X; Qiu HY; Zhao MY; Zhu HL
Org Biomol Chem; 2013 Oct; 11(37):6328-37. PubMed ID: 23942809
[TBL] [Abstract][Full Text] [Related]
26. Novel inhibitors of the v-raf murine sarcoma viral oncogene homologue B1 (BRAF) based on a 2,6-disubstituted pyrazine scaffold.
Niculescu-Duvaz I; Roman E; Whittaker SR; Friedlos F; Kirk R; Scanlon IJ; Davies LC; Niculescu-Duvaz D; Marais R; Springer CJ
J Med Chem; 2008 Jun; 51(11):3261-74. PubMed ID: 18473434
[TBL] [Abstract][Full Text] [Related]
27. NO-releasing STAT3 inhibitors suppress BRAF-mutant melanoma growth.
Kaoud TS; Mohassab AM; Hassan HA; Yan C; Van Ravenstein SX; Abdelhamid D; Dalby KN; Abdel-Aziz M
Eur J Med Chem; 2020 Jan; 186():111885. PubMed ID: 31784187
[TBL] [Abstract][Full Text] [Related]
28. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
[TBL] [Abstract][Full Text] [Related]
29. Light-controlled inhibition of BRAFV600E kinase.
Hoorens MWH; Ourailidou ME; Rodat T; van der Wouden PE; Kobauri P; Kriegs M; Peifer C; Feringa BL; Dekker FJ; Szymanski W
Eur J Med Chem; 2019 Oct; 179():133-146. PubMed ID: 31252305
[TBL] [Abstract][Full Text] [Related]
30. Development of a novel chemical class of BRAF inhibitors offers new hope for melanoma treatment.
Smalley KS; Flaherty KT
Future Oncol; 2009 Aug; 5(6):775-8. PubMed ID: 19663727
[TBL] [Abstract][Full Text] [Related]
31. Mitochondrial complex I inhibitor deguelin induces metabolic reprogramming and sensitizes vemurafenib-resistant BRAF
Carpenter EL; Chagani S; Nelson D; Cassidy PB; Laws M; Ganguli-Indra G; Indra AK
Mol Carcinog; 2019 Sep; 58(9):1680-1690. PubMed ID: 31211467
[TBL] [Abstract][Full Text] [Related]
32. Identification of novel 3,5-diarylpyrazoline derivatives containing salicylamide moiety as potential anti-melanoma agents.
Li QS; Lv XH; Zhang YB; Dong JJ; Zhou WP; Yang Y; Zhu HL
Bioorg Med Chem Lett; 2012 Nov; 22(21):6596-601. PubMed ID: 23025996
[TBL] [Abstract][Full Text] [Related]
33. Genotype-dependent cooperation of ionizing radiation with BRAF inhibition in BRAF V600E-mutated carcinomas.
Dasgupta T; Haas-Kogan DA; Yang X; Olow A; Yang DX; Gragg A; Orloff LA; Yom SS
Invest New Drugs; 2013 Oct; 31(5):1136-41. PubMed ID: 23354848
[TBL] [Abstract][Full Text] [Related]
34. Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors.
Shi H; Moriceau G; Kong X; Koya RC; Nazarian R; Pupo GM; Bacchiocchi A; Dahlman KB; Chmielowski B; Sosman JA; Halaban R; Kefford RF; Long GV; Ribas A; Lo RS
Cancer Discov; 2012 May; 2(5):414-24. PubMed ID: 22588879
[TBL] [Abstract][Full Text] [Related]
35. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner.
Joseph EW; Pratilas CA; Poulikakos PI; Tadi M; Wang W; Taylor BS; Halilovic E; Persaud Y; Xing F; Viale A; Tsai J; Chapman PB; Bollag G; Solit DB; Rosen N
Proc Natl Acad Sci U S A; 2010 Aug; 107(33):14903-8. PubMed ID: 20668238
[TBL] [Abstract][Full Text] [Related]
36. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
[TBL] [Abstract][Full Text] [Related]
37. The first small molecules capable of strongly suppressing proliferation of cancer cells harboring BRAF class I/II/III mutations.
Choi SH; Shin I; Kim N; Nam Y; Sim T
Biochem Biophys Res Commun; 2020 Nov; 532(2):315-320. PubMed ID: 32873393
[TBL] [Abstract][Full Text] [Related]
38. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.
Nazarian R; Shi H; Wang Q; Kong X; Koya RC; Lee H; Chen Z; Lee MK; Attar N; Sazegar H; Chodon T; Nelson SF; McArthur G; Sosman JA; Ribas A; Lo RS
Nature; 2010 Dec; 468(7326):973-7. PubMed ID: 21107323
[TBL] [Abstract][Full Text] [Related]
39. Insight into molecular dynamics simulation of BRAF(V600E) and potent novel inhibitors for malignant melanoma.
Tang HC; Chen YC
Int J Nanomedicine; 2015; 10():3131-46. PubMed ID: 25960652
[TBL] [Abstract][Full Text] [Related]
40. Design, synthesis and biological evaluation of benzyl 2-(1H-imidazole-1-yl) pyrimidine analogues as selective and potent Raf inhibitors.
Kim M; Lee J; Jung K; Kim H; Aman W; Ryu JS; Hah JM
Bioorg Med Chem Lett; 2014 Aug; 24(15):3600-4. PubMed ID: 24878193
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
